Phase II Study of Neoadjuvant Chemotherapy With S-1 and CDDP in Patients With Lymph Node Metastatic Stage II or III Gastric Cancer
| Autor: | Hidenori Tamegai, Megumu Watanabe, Tomoya Funada, Yoshiaki Mihara, Yuriko Takayama, Noriaki Kanamori, Tadatoshi Takayama, Masashi Fujii, Hiroshi Suda, Mitsugu Kochi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Locally advanced Phases of clinical research Antineoplastic Agents Stage ii 03 medical and health sciences 0302 clinical medicine Stomach Neoplasms Internal medicine medicine Humans In patient 030212 general & internal medicine Lymph node Aged Neoplasm Staging Tegafur Cisplatin Chemotherapy business.industry Cancer Middle Aged medicine.disease Neoadjuvant Therapy Drug Combinations Oxonic Acid medicine.anatomical_structure Lymphatic Metastasis 030220 oncology & carcinogenesis Female business medicine.drug |
| Zdroj: | American Journal of Clinical Oncology. 40:17-21 |
| ISSN: | 0277-3732 |
| DOI: | 10.1097/coc.0000000000000058 |
| Popis: | We conducted a phase II trial to investigate the efficacy and safety of neoadjuvant chemotherapy (NAC) comprising S-1 and cisplatin (CDDP) followed by extensive resection in the management of resectable locally advanced gastric cancer with lymph node (LN) metastases.Patients with LN metastases from stage II or III gastric cancer received S-1 and CDDP, as NAC criteria for LN metastases were the involvement of ≥4 nodes2 cm or ≥1 nodes ≥2 cm as confirmed by a total body computed tomography scan. All patients underwent extensive resection including D2 gastrectomy. The primary endpoint was complete resection rate and the secondary endpoints were 3-year relapse-free and overall survival.Fifty patients were assessable for the analysis. The complete resection rate was 87.8%. Three-year relapse-free survival was 44.9% and 3-year overall survival rate was 48.0%.NAC with S-1 and CDDP is safe and may improve the complete resection rate in patients with metastatic LN gastric cancer. This suggests that LN metastases would provide good target lesions in future clinical trials of NAC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|